IGFBP4 Recombinant Rabbit mAb (SDT-187-5)
IGFBP4 Recombinant Rabbit mAb (SDT-187-5)
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | IGFBP4 |
| Synonyms | IBP-4, IGF-binding protein 4, IGFBP-4 |
| Immunogen | Synthetic Peptide |
| Location | N/A |
| Accession | P22692 |
| Clone Number | SDT-187-5 |
| Antibody Type | Recombinant mAb |
| Application | Sandwich ELISA |
| Reactivity | Hu |
| Cross Reactivity | Recognize IGFBP4-CT, does not recognize full-length IGFBP4 |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Purity | >95% by HPLC |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
| application | dilution | species |
| Sandwich ELISA | S0B3109 as capture antibody pair with other detection antibody, S0B3109 recognized human CT-IGFBP-4, low cross-reaction with full-length human IGFBP-4 (ELISA) |
Background
The protein binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma in both glycosylated and non-glycosylated forms. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. IGFBP-4 is a unique protein and it consistently inhibits several cancer cells in vivo and in vitro. Its inhibitory action has been shown in vivo in prostate and colon. It is secreted by all colon cancer cells. Recent studies have indicated that IGFBP-4 fragments can predict adverse cardiac events in acute coronary syndrome patients Some inventions describes a method for diagnosing of cardiovascular diseases, which comprises detection of IGFBP-4 (insulin-like growth factor binding protein-4) fragments in patients’ blood. It provides antibodies as well as epitopes for antibodies, specific to proteolytic fragments (both N- and C-terminal) of IGFBP-4 originated from IGFBP-4 molecule after its cleavage by specific protease PAPP-A. Antibodies could be used for development of immunoassay methods for quantitative or qualitative detection of IGFBP-4 fragments in human blood.
